We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
- Recent MESO Stock Price: $2.87
- Yearly Gain for MESO stock: -54.00%
- Market Cap for MESO stock: $422.33M
- P/E Ratio for MESO stock: -4.162
Will MESO's stock price go up? Is there an accurate MESO stock forecast available?
TipRanks.com reports that Mesoblast currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $6.50. The target pricing ranges from a high MESO forecast of $10.00 down to a low forecast of $2.50. Mesoblast (MESO)’s last closing stock price was $2.87 which would put the average price target at 126.48% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MESO stock.
Other analysts covering MESO include:
- Jason McCarthy of Maxim Group issued a Buy rating with the price target of $ 10 on 5 days ago
- Keay Nakae of Chardan Capital issued a Sell rating with the price target of $ 2.5 on 6 days ago
- Swayampakula Ramakanth of H.C. Wainwright issued a Buy rating with the price target of $ 16 on 3 months ago
If you are wondering if MESO is a good stock to buy, here are 3rd party ratings for MESO stock:
- TipRanks.com: Hold
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 26% (66 out of 252)
What is the sentiment on the street regarding Mesoblast? (Current ratings compiled by TipRanks.com)
- News Sentiment for MESO stock: Neutral
- Blogger Consensus for MESO stock: n/a
- Media Buzz for MESO stock: Medium
- Insider Signal for MESO stock: n/a
- Investor Sentiment for MESO stock: Neutral
- Hedge Fund signal for MESO stock: No Signal
The stock market is extremely volatile, and you need to do your own research on MESO stock including scouring the social networks like MESO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MESO stock chart >>
Summary: Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States.
- Recent AQST Stock Price: $1.25
- Yearly Gain for AQST stock: -71.08%
- Market Cap for AQST stock: $69.89M
- P/E Ratio for AQST stock: -0.742
Will AQST's stock price go up? Is there an accurate AQST stock forecast available?
TipRanks.com reports that Aquestive Therapeutics currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $5.33. The target pricing ranges from a high AQST forecast of $7.00 down to a low forecast of $4.00. Aquestive Therapeutics (AQST)’s last closing stock price was $1.25 which would put the average price target at 326.40% upside.
In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AQST stock.
Other analysts covering AQST include:
- Jason Butler of JMP Securities issued a Buy rating with the price target of $ 7 on 6 days ago
- Liana Moussatos of Wedbush issued a Buy rating with the price target of $ 4 on 6 days ago
- Thomas Flaten of Lake Street issued a Buy rating with the price target of $ 7 on 3 months ago
- Gary Nachman of BMO Capital issued a Buy rating with the price target of $ 9 on 4 months ago
If you are wondering if AQST is a good stock to buy, here are 3rd party ratings for AQST stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 31% (79 out of 252)
What is the sentiment on the street regarding Aquestive Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for AQST stock: Very Bullish
- Blogger Consensus for AQST stock: Bullish
- Media Buzz for AQST stock: Low
- Insider Signal for AQST stock: Positive
- Investor Sentiment for AQST stock: Neutral
- Hedge Fund signal for AQST stock: Neutral
The stock market is extremely volatile, and you need to do your own research on AQST stock including scouring the social networks like AQST StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AQST stock chart >>
Summary: Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
- Recent ILMN Stock Price: $201.02
- Yearly Gain for ILMN stock: -58.01%
- Market Cap for ILMN stock: $30.84B
- P/E Ratio for ILMN stock: -2405.766
Will ILMN's stock price go up? Is there an accurate ILMN stock forecast available?
TipRanks.com reports that Illumina currently has 14 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $252.92. The target pricing ranges from a high ILMN forecast of $380.00 down to a low forecast of $130.00. Illumina (ILMN)’s last closing stock price was $201.02 which would put the average price target at 25.82% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on ILMN stock.
Other analysts covering ILMN include:
- David Westenberg of Piper Sandler issued a Buy rating with the price target of $ 320 on 1 day ago
- Dan Leonard of Credit Suisse issued a Hold rating with the price target of $ 230 on 1 week ago
If you are wondering if ILMN is a good stock to buy, here are 3rd party ratings for ILMN stock:
- TipRanks.com: Hold
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Strong Sell, Top 26% (66 out of 252)
What is the sentiment on the street regarding Illumina? (Current ratings compiled by TipRanks.com)
- News Sentiment for ILMN stock: Very Bullish
- Blogger Consensus for ILMN stock: Bullish
- Media Buzz for ILMN stock: High
- Insider Signal for ILMN stock: n/a
- Investor Sentiment for ILMN stock: Positive
- Hedge Fund signal for ILMN stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ILMN stock including scouring the social networks like ILMN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ILMN stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================